Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years af­ter then-Am­gen R&D chief Sean Harp­er tamped the last spade of dirt on the last broad­ly fo­cused CETP cho­les­terol drug — bury­ing their $300 mil­lion up­front and the few re­main­ing hopes for the class with it — the ther­a­py has been ful­ly res­ur­rect­ed. And to­day, the NewAms­ter­dam Phar­ma crew that did the Lazarus treat­ment on obice­trapib is tak­ing an­oth­er big step on the come­back trail with a €1 bil­lion-plus re­gion­al li­cens­ing deal, com­plete with close to $150 mil­lion in up­front cash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.